Abstract
It has been over 50 years since the discovery of interferon. While initially touted as “the wonder drug” for cancer therapy, the reality of interferon use as a treatment for cancer has been far different. Today, interferon is used predominantly as adjuvant therapy in renal cell carcinoma and melanoma and is being evaluated for potential new applications in other malignancies, including leukemias, lymphomas, ovarian and prostate cancer, and tumors of the central nervous system. In this review we will discuss the outcome and challenges of interferon administration in malignancies and the future of this first “cytokine” in cancer therapy.
Keywords: Interferon, PEG-Intron, cytokine, cancer, malignancy, tumor, anti-tumor drugs
Current Drug Therapy
Title: Interferon Therapy for Malignant Solid Tumors
Volume: 5 Issue: 2
Author(s): Katherine E. Warren and Howard A. Young
Affiliation:
Keywords: Interferon, PEG-Intron, cytokine, cancer, malignancy, tumor, anti-tumor drugs
Abstract: It has been over 50 years since the discovery of interferon. While initially touted as “the wonder drug” for cancer therapy, the reality of interferon use as a treatment for cancer has been far different. Today, interferon is used predominantly as adjuvant therapy in renal cell carcinoma and melanoma and is being evaluated for potential new applications in other malignancies, including leukemias, lymphomas, ovarian and prostate cancer, and tumors of the central nervous system. In this review we will discuss the outcome and challenges of interferon administration in malignancies and the future of this first “cytokine” in cancer therapy.
Export Options
About this article
Cite this article as:
E. Warren Katherine and A. Young Howard, Interferon Therapy for Malignant Solid Tumors, Current Drug Therapy 2010; 5 (2) . https://dx.doi.org/10.2174/157488510791065058
DOI https://dx.doi.org/10.2174/157488510791065058 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tubulin Inhibitors: A Patent Survey
Recent Patents on Anti-Cancer Drug Discovery Antiplatelet Therapies: Platelet GPIIb / IIIa Antagonists and Beyond
Current Pharmaceutical Design Chronopharmacology and Antimicrobial Therapeutics
Current Clinical Pharmacology Extraction and Evaluation of Anti-inflammatory and Analgesic Activity of Mimosa rubicaulis in Swiss Albino Rats
Anti-Infective Agents Stimulation of Tumor-Specific Immunity by p5 HER-2/neu Generated Peptide Encapsulated in Nano-liposomes with High Phase Transition Temperature Phospholipids
Current Drug Delivery VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets Therapeutic Agents Based on DNA Sequence Specific Binding
Current Topics in Medicinal Chemistry Multimodality Imaging of CXCR4 in Cancer: Current Status towards Clinical Translation
Current Molecular Medicine Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting the Eph-ephrin System with Protein-Protein Interaction (PPI) Inhibitors
Current Drug Targets Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
Current Cancer Drug Targets Identification of the Multifaceted Chemopreventive Activity of Curcumin Against the Carcinogenic Potential of the Food Additive, KBrO3
Current Pharmaceutical Design Challenges and Controversies in Autoantibodies Associated with Systemic Rheumatic Diseases
Current Rheumatology Reviews Nucleic Acid Carrier Systems Based on Polyethylenimine Conjugates for the Treatment of Metastatic Tumors
Current Medicinal Chemistry Fabrication and Characterization of Fungal Chitosan-SAP Membranes for Hemostatic Application
Current Biochemical Engineering (Discontinued) Targeted – Therapy and Imaging Response: A New Paradigm For Clinical Evaluation?
Reviews on Recent Clinical Trials Role of NF-κB in the Regulation of Cytochrome P450 Enzymes
Current Drug Metabolism Role of Vascular Endothelial Growth Factor in Kidney Disease
Current Vascular Pharmacology Electroporation Gene Therapy: New Developments In Vivo and In Vitro
Current Gene Therapy Models to Predict Intestinal Absorption of Therapeutic Peptides and Proteins
Current Drug Metabolism